• Home >
  • Publications >
  • Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab

Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab

1 May 2020Journal of Nuclear Medicine

DOI : 10.2967/jnumed.119.232827

Authors

Aiping Chen, Fatima-Zohra Mokrane, Lawrence H. Schwartz, Franck Morschhauser, Apasia Stamatoullas, Jean-Marc Schiano de Colella, Laetitia Vercellino, Olivier Casasnovas, Adrien Chauchet, Alain Delmer, Emmanuelle Nicolas-Virelizier, Hervé Ghesquières, Marie-Pierre Moles-Moreau, Anna Schmitt, Rémy Dulery, Krimo Bouabdallah, Cecile Borel, Mohamed Touati, Benedicte Deau-Fischer, Frédéric Peyrade, Romain-David Seban, Guillaume Manson, Philippe Armand, Roch Houot, Laurent Dercle